**DHT: Board Resolution No. 740**

On August 29, 2024, HaTay Pharmaceutical JSC announced Resolution No. 740/NQ-DHT on approving the opinions for the public offering of HaTay Pharmaceutical JSC’s shares as follows:

Article 1. Approve the opinions for the public offering of the Company’s shares (securities code: DHT) as follows:

After receiving and reviewing the public offering dossier for the Company's shares (securities code: DHT) from ASKA Pharmaceutical Co., Ltd. as disclosed on August 27, 2024, the Board of Directors had the following opinions:

* Agree with the proposal of ASKA Pharmaceutical Co., Ltd. on the public offering and request ASKA Pharmaceutical Co., Ltd. to implement the public offering in accordance with current provisions of Vietnamese law.
* The Board of Directors will coordinate the implementation of work in accordance with the provisions of Vietnamese law during the process of ASKA Pharmaceutical Co., Ltd. implementing the public offering.

‎‎Article 2. Approve the authorization for the General Manager of the Company as follows:

Approve on authorizing the General Manager of the Company to decide on contents, implement tasks, and sign necessary documents according to the provisions of law (including but not limited to disclosing information and reporting to competent authorities) to complete the public offering as requested by ASKA Pharmaceutical Co., Ltd.

Article 3. The Board of Directors of HaTay Pharmaceutical JSC, the Board of Management, and relevant departments, divisions, and units are responsible for implementing this Resolution.

This Resolution takes effect from the date of its signing./.